Home › Funds › Frazier Life Sciences Management, L.P. › ACRS
Frazier Life Sciences Management, L.P. position in ACRS
ACLARIS THERAPEUTICS INC · Health Care
Frazier Life Sciences Management, L.P. reported holding 4,925,374 shares of ACRS (ACLARIS THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$26.1M, representing 0.57% of its reported portfolio and ranking #29 among its reported holdings. Frazier Life Sciences Management, L.P. has disclosed ACRS holdings in 7 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Frazier Life Sciences Management, L.P.'s ACRS position evolved
Frazier Life Sciences Management, L.P. first disclosed a stake in ACRS in Q3 2023 at 264,377 shares (US$1.8M). The position peaked in Q2 2026 at 4,925,374 shares, worth US$26.1M. Across 7 filings, Frazier Life Sciences Management, L.P. held the position steady without any share-count change. The most recent filing (Q2 2026) shows 4,925,374 shares valued at US$26.1M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 264.38K | $1.81M | New |
| Q4 2023 | 264.38K | $277.60K | Hold |
| Q1 2024 | 264.38K | $327.83K | Hold |
| Q2 2024 | 264.38K | $290.81K | Hold |
| Q3 2024 | 264.38K | $304.03K | Hold |
| Q1 2026 | 4.93M | $18.47M | New |
| Q2 2026 | 4.93M | $26.06M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ACRS and 13F data
ACRS (ACLARIS THERAPEUTICS INC) is a Health Care company. 43 other funds we track also report a position in ACRS — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$67.3M), BML Capital Management, LLC (US$63.3M), Deep Track Capital, LP (US$49.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ACRS
- RA CAPITAL MANAGEMENT, L.P. 12.72M sh · $67.30M · Q2 2026
- BML Capital Management, LLC 11.97M sh · $63.35M · Q2 2026
- Deep Track Capital, LP 9.35M sh · $49.44M · Q2 2026
- Vivo Capital, LLC 6.69M sh · $35.41M · Q2 2026
- Rock Springs Capital Management LP 4.33M sh · $22.91M · Q2 2026
- Decheng Capital LLC 4.04M sh · $21.38M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 1.95M sh · $10.30M · Q2 2026
- Kalehua Capital Management LLC 1.83M sh · $9.69M · Q2 2026
- Jones Hill Capital LP 1.76M sh · $9.31M · Q2 2026
- Palo Alto Investors LP 1.61M sh · $8.54M · Q2 2026
- MPM BioImpact LLC 1.04M sh · $5.51M · Q2 2026
- Aldebaran Capital, LLC 936.73K sh · $4.96M · Q2 2026
More on Frazier Life Sciences Management, L.P.
FAQ
How long has Frazier Life Sciences Management, L.P. held ACRS?
Frazier Life Sciences Management, L.P. has disclosed ACRS holdings in 7 of the last 12 reported quarters, going back to Q3 2023.
What is Frazier Life Sciences Management, L.P.'s current position in ACRS?
As of Q2 2026, Frazier Life Sciences Management, L.P. holds 4.93M shares of ACRS (ACLARIS THERAPEUTICS INC), valued at $26.06M, representing 0.57% of its reported portfolio and ranking #29.
Has Frazier Life Sciences Management, L.P. been buying or selling ACRS?
In the latest 13F filing (Q2 2026), Frazier Life Sciences Management, L.P. held unchanged its position in ACRS. The position peaked in Q2 2026 at 4.93M shares.
Which other funds hold ACRS?
Other major institutional holders of ACRS include RA CAPITAL MANAGEMENT, L.P., BML Capital Management, LLC, Deep Track Capital, LP, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.